Research progress of prognostic biomarkers in diffuse large B-cell lymphoma
10.3760/cma.j.cn112152-20191125-00756
- VernacularTitle:弥漫大B细胞淋巴瘤预后相关分子标志物的研究进展
- Author:
Haizhu CHEN
1
;
Yuankai SHI
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院内科 抗肿瘤分子靶向药物临床研究北京市重点实验室 100021
- Keywords:
Diffuse large B-cell lymphoma;
Prognosis;
Biomarker
- From:
Chinese Journal of Oncology
2020;42(12):989-995
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous malignancy. A variety of indicators have been identified to predict the prognosis of DLBCL. However, with the emerging new drugs and new therapeutic options in recent years, the prognostic value of these risk prediction models becomes limited, failing to accurately guide treatment. The rapid development of high throughput technologies has led to dramatic improvement in understanding of the biology of DLBCL. The emergence of various new biomarkers contributes to further understanding the pathogenesis, treatment optimization and prognostic stratification of this disease. This review summarizes the prognostic biomarkers related to DLBCL, which mainly covers the hematological, genetic and tumor microenvironment factors, aiming to provide some theoretical basis for the precision treatment of DLBCL.
